back to Australia directory
australia clinical guidance

Asthma

A detailed Australian summary of asthma, with source-attributed priorities, a practical workflow, safety escalation and state or territory implementation boundaries.

JurisdictionAustralia
Source check2026-08-20
Clinical reviewiatroX editorial team 路 Clinical editorial review 路 reviewed 2026-08-20 路 due 2027-08-20
AudienceHealthcare professionals practising in Australia
This is an iatroX educational summary of named Australia sources, not an official guideline. It does not replace the complete source documents, local policy, specialist advice or clinical judgement. Apply current TGA product information, PBS restrictions, state or territory law, local referral criteria, formulary and antimicrobial policy. A national recommendation does not create uniform service access.

Scope

Base diagnosis on a compatible pattern of variable respiratory symptoms plus objective evidence of variable expiratory airflow limitation whenever testing is possible. Australian adult and adolescent pathways use inhaled-corticosteroid-containing treatment at every level; ongoing short-acting bronchodilator-only treatment is not recommended. This summary is limited to the population, decisions and escalation boundaries stated in the named source.
sources for this section:Australian Asthma Handbook v3.0

The Bottom Line

  • Base diagnosis on a compatible pattern of variable respiratory symptoms plus objective evidence of variable expiratory airflow limitation whenever testing is possible.
  • Australian adult and adolescent pathways use inhaled-corticosteroid-containing treatment at every level; ongoing short-acting bronchodilator-only treatment is not recommended.
  • Demonstrate bronchodilator reversibility or another Handbook-approved variability pathway and interpret a negative test in relation to current corticosteroid exposure.
  • As-needed budesonide鈥揻ormoterol is the preferred initial AIR pathway for many people aged twelve years or older, subject to product approval and individual risk.
sources for this section:Australian Asthma Handbook v3.0

Practical clinical workflow

1

Topic-specific assessment action

Base diagnosis on a compatible pattern of variable respiratory symptoms plus objective evidence of variable expiratory airflow limitation whenever testing is possible.
2

Topic-specific diagnostic action

As-needed budesonide鈥揻ormoterol is the preferred initial AIR pathway for many people aged twelve years or older, subject to product approval and individual risk.
3

Topic-specific management action

Before stepping up, verify diagnosis, adherence and device technique, then address smoking, allergens, rhinitis, reflux and other modifiable contributors.
4

Topic-specific follow-through

Check reliever frequency and every oral-corticosteroid course because exacerbation history changes future-risk assessment even when today鈥檚 symptoms are mild.
sources for this section:Australian Asthma Handbook v3.0

Safety boundaries and escalation

  • Provide an individual written action plan and urgently escalate marked breathlessness, inability to speak, exhaustion, cyanosis, altered consciousness or poor bronchodilator response.
  • Review asthma after an acute attack to correct technique, adherence and trigger exposure and update the written action plan.
sources for this section:Australian Asthma Handbook v3.0

Implementation

The named source is national or binational guidance used in Australia, but referral access, public-health directions, formularies and funded services can still differ by state, territory and health service. Check current TGA product information for medicines. Offer culturally safe care and use the NACCHO鈥揜ACGP National Guide where Aboriginal and Torres Strait Islander preventive or chronic-care recommendations differ.
sources for this section:Australian Asthma Handbook v3.0

Clinical use boundary

This independently written summary is not an official guideline. Check the linked source version, current TGA-approved product information where medicines are involved, and the applicable state, territory and local pathway at the point of care.

sources for this section:Australian Asthma Handbook v3.0

Source documents

Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.

  1. National Asthma Council AustraliaAustralian Asthma Handbook: The National Guidelines for Health ProfessionalsVersion 3.0, September 2025 路 accessed 2026-08-20
    view source
continue the learning

From guidance to deliberate practice and evidence

Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.

Add this guidance review to CPD/CMEOpen an editable learning-log record with this page鈥檚 provenance attached. You confirm the activity, time, reflection and mappings.Reflect on this with TutorUse optional prompts to consider what you learned and what鈥攊f anything鈥攜ou may change. Suggestions are never inserted automatically.Browse the Australia question bankKeep this guidance topic in view, then choose your exam and filters. No session starts automatically.
Found a source update or regional discrepancy? Tell the iatroX editorial team.